BlossomHill Therapeutics Analyst Price Targets

BlossomHill Therapeutics Inc

BLSMNASDAQ

Trade with Public

$13.94

-1.04-6.94%

Dern. MÀJ: Oct 15, 4:00 PM

$14.98

N/A

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Rapport sur les stocks

BlossomHill Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for BlossomHill Therapeutics (BLSM).

Price Target Range — 1 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$34Upside to Avg. PT+128.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 21, 2026	Leerink Partners	—	PT Raise	Outperform	$36→$40
Sep 21, 2026	Guggenheim	Michael Schmitz	PT Raise	Buy	$30→$40
Sep 1, 2026	LifeSci Capital	—	Initiate	Outperform	$32
Sep 1, 2026	Leerink Partners	—	Initiate	Outperform	$36
Sep 1, 2026	JP Morgan	Brian Cheng	Initiate	Overweight	$28
Sep 1, 2026	Guggenheim	Michael Schmidt	Initiate	Buy	$30
Sep 1, 2026	HC Wainwright & Co.	Robert Burns	Initiate	Buy	$35

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40

Leerink Partners maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform and raises the price target from $36 to $40.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40

Guggenheim analyst Michael Schmitz maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy and raises the price target from $30 to $40.

Benzinga Newsdesk

PRO
LifeSci Capital Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $32

LifeSci Capital initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform rating and announces Price Target of $32.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $36

Leerink Partners initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Outperform rating and announces Price Target of $36.

Benzinga Newsdesk

PRO
JP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28

JP Morgan analyst Brian Cheng initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Overweight rating and announces Price Target of $28.

Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30

Guggenheim analyst Michael Schmidt initiates coverage on BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy rating and announces Price Target of $30.

Benzinga Newsdesk

BlossomHill Therapeutics Inc

BlossomHill Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40

PRO
Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40

PRO
LifeSci Capital Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $32

PRO
Leerink Partners Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $36

PRO
JP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28

PRO
Guggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

BlossomHill Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40

PRO
Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40

PRO
LifeSci Capital Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $32

PRO
Leerink Partners Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $36

PRO
JP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28

PRO
Guggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30

People Also Watch

People Also Watch

BlossomHill Therapeutics Inc

BlossomHill Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLeerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40

PROGuggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40

PROLifeSci Capital Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $32

PROLeerink Partners Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $36

PROJP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28

PROGuggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

BlossomHill Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLeerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40

PROGuggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40

PROLifeSci Capital Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $32

PROLeerink Partners Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $36

PROJP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28

PROGuggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30

People Also Watch

People Also Watch

PRO
Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40

PRO
Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40

PRO
LifeSci Capital Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $32

PRO
Leerink Partners Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $36

PRO
JP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28

PRO
Guggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30

PRO
Leerink Partners Maintains Outperform on BlossomHill Therapeutics, Raises Price Target to $40

PRO
Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40

PRO
LifeSci Capital Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $32

PRO
Leerink Partners Initiates Coverage On BlossomHill Therapeutics with Outperform Rating, Announces Price Target of $36

PRO
JP Morgan Initiates Coverage On BlossomHill Therapeutics with Overweight Rating, Announces Price Target of $28

PRO
Guggenheim Initiates Coverage On BlossomHill Therapeutics with Buy Rating, Announces Price Target of $30